Madrigal Pharmaceuticals Inc (MDGL) CEO Paul A Friedman Sold $21.1 million of Shares

CEO of Madrigal Pharmaceuticals Inc (MDGL, Financial) Paul A Friedman sold 73,526 shares of MDGL on 06/11/2018 at an average price of $287.46 a share. The total sale was $21.1 million.

Madrigal Pharmaceuticals Inc is a company focused on the development of novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). Madrigal Pharmaceuticals Inc has a market cap of $4.03 billion; its shares were traded at around $282.71 . Madrigal Pharmaceuticals Inc had annual average EBITDA growth of 43.80% over the past five years.

CEO Recent Trades:

  • CEO Paul A Friedman sold 73,526 shares of MDGL stock on 06/11/2018 at the average price of $287.46. The price of the stock has decreased by 1.65% since.

Directors and Officers Recent Trades:

  • Director, 10% Owner Fred B Craves sold 280,000 shares of MDGL stock on 06/11/2018 at the average price of $287.46. The price of the stock has decreased by 1.65% since.
  • Chief Medical Officer, EVP R&D Rebecca Taub sold 73,526 shares of MDGL stock on 06/11/2018 at the average price of $287.46. The price of the stock has decreased by 1.65% since.
  • Director, 10% Owner City Capital Llc Bay sold 280,000 shares of MDGL stock on 06/11/2018 at the average price of $287.46. The price of the stock has decreased by 1.65% since.

For the complete insider trading history of MDGL, click here

.